ASX Release 16 November 2026

Gleneagles Hospital CEO appointed to Chair Advisory Board alongside globally recognised renal expert

Highlights:

- **Internationally recognised kidney injury expert joins Advisory Board:** Professor Kwok-ming Ho brings over 30 years of intensive care experience and extensive AKI research expertise directly aligned with Nexsen's advancing RenalSure® diagnostics programme.
- **Gleneagles Hospital CEO appointed Advisory Board Chair:** Dr Kenneth Tsang brings extensive hospital leadership, healthcare strategy and commercialisation experience across Asia.
- **Advisory Board to support clinical development and commercialisation:** Refreshed Advisory Board will provide strategic guidance across diagnostic development, clinical validation, regulatory pathways and hospital adoption, supporting commercialisation of Nexsen's diagnostics portfolio.

Nexsen Limited (**ASX:NXN**) ("**Nexsen**" or the "**Company**") is pleased to advise it has significantly strengthened its Advisory Board, with the appointments of Dr Kenneth Tsang as Chair and internationally recognised intensive care specialist Professor Kwok-ming Ho joining as a new member.

The appointments bring significant hospital leadership and specialist clinical expertise to Nexsen, supporting the development, validation and future adoption of its growing portfolio of rapid point-of-care diagnostics.



Dr Kenneth Tsang, Advisory Board Chair

Nexsen Non-Executive Chairman, Reece O'Connell, said:

"Attracting advisors of this calibre is a tremendous achievement and reflects the scale of the opportunity we are working towards. Professor Ho brings exceptional clinical expertise in Acute Kidney Injury, supporting one

of our most significant diagnostic opportunities. His understanding of the challenges facing intensive care clinicians will be invaluable as we advance RenalSure® towards clinical validation and regulatory submission.

"Having Kenneth, who leads Gleneagles Hospital Hong Kong and IHH Healthcare's North Asia operations, chair our Advisory Board is equally significant. His experience at the highest levels of hospital management brings an important commercial perspective as we build pathways towards clinical adoption.

"We have ambitious plans for Nexsen, and bringing together this level of clinical and healthcare leadership puts us in a stronger position to deliver on them."

Dr Kenneth Tsang, Advisory Board Chair

Dr Kenneth Tsang is Chief Executive Officer of Gleneagles Hospital Hong Kong, a 500-bed private teaching hospital affiliated with The University of Hong Kong, and Regional Chief Executive Officer of IHH Healthcare North Asia which operate a network of 190 healthcare facilities globally.

With over 30 years of healthcare experience, including senior leadership positions within Hong Kong's Hospital Authority, Dr Tsang brings extensive expertise in hospital operations, clinical innovation and healthcare strategy.

His appointment as Chair strengthens Nexsen's commercial and clinical capabilities, bringing valuable insight into hospital decision-making, clinical adoption and the introduction of new medical technologies across Asian healthcare markets.

Professor Kwok-ming Ho, Advisory Board Member

Professor Kwok-ming Ho is Chair of the Department of Anaesthesia and Intensive Care at The Chinese University of Hong Kong and an internationally recognised intensive care specialist and clinical researcher with decades of experience treating critically ill patients and conducting research across Acute Kidney Injury (AKI), sepsis and traumatic brain injury.

He has authored or co-authored more than 390 scientific publications, including research published in the *New England Journal of Medicine*, *British Medical Journal* and *Intensive Care Medicine*, and has contributed to research programmes attracting over A$7 million in competitive grant funding.

His appointment is particularly timely following Nexsen's recent announcement on its AKI diagnostics programme, including the advancement of RenalSure® towards a targeted US FDA submission in mid-2027. Professor Ho's extensive research into kidney injury, biomarkers and monitoring in intensive care will provide valuable clinical insight to support diagnostic development, clinical validation and integration into hospital workflows.

Refreshed Advisory Board

The Advisory Board will comprise Dr Kenneth Tsang (Chair), Professor Kwok-ming Ho, Professor Shekhar Kumta and Managing Director Mark Muzzin.

As part of the changes, Associate Professor Prahlad Ho and Professor Vipul Bansal have transitioned from the Advisory Board. Nexsen thanks them both for their valuable contribution to the Company's development.

-ENDS-

ASX release authorised by the Board of Directors.

For more information, please contact:

Corporate Enquiries

e: corporate@nexsen.bio

w: www.nexsen.bio

a: Level 8, 216 St Georges Tce
Perth WA 6000

Company Secretary

e: ab@nexsen.bio

p: +61 418 342 762

Investor Relations

e: freddie.edwards@sdir.com.au

p: +61 431 726 210

About Nexsen Limited (ASX: NXN)

Nexsen is developing a growing portfolio of rapid point-of-care diagnostics for serious conditions where delays in diagnosis can affect patient outcomes and limit the ability of clinicians to make fast, informed treatment decisions. The Company's lead programmes include diagnostics for Group B Streptococcus (GBS) in maternal health and kidney function, targeting Acute Kidney Injury and Chronic Kidney Disease. Nexsen is also advancing programmes across traumatic brain injury, neonatal sepsis and biosecurity, supported by an international research, clinical and commercial network across Australia and Asia.

Forward Looking Statements Disclaimer

Forward looking statements are typically identified by the use of forward looking terminology such as 'aims', 'believes', 'expects', 'may', 'will', 'could', 'should', 'seeks', 'intends', 'estimates', 'plans', 'assumes', 'envisages', or the negative thereof or other words of similar meaning. Examples of such forward looking statements include, among others, statements or discussions regarding the Company's business, financial or investment strategies, regulatory and product rollout strategies, estimates of expenditure, present or future plans or events, prospects, growth, objectives for future operations and estimates. Such forward looking statements include matters that are not historical facts and are subject to a number of risks and uncertainties, many of which are beyond the Company's control and all of which are based on the Company's current beliefs, intentions or expectations about future events. Such statements are, by their nature, subject to a number of known and unknown risks, uncertainties, assumptions and other important factors that could cause actual results, performance or achievements to differ materially from any expected future results, performance or achievements expressed or implied, by the forward looking statement.

Neither the Company nor any person gives any representation, assurance or guarantee that the occurrence of the event expressed or implied in any forward looking statements in this document will actually occur and you are cautioned not to place undue reliance on such forward looking statements. Factors that might cause forward looking statements to differ materially from actual results, performance or achievements include, among other things, global economic conditions, economic conditions in jurisdictions in which the Company may operate or invest, credit markets, legislative fiscal and regulatory developments, the effects of continued volatility in markets and exchange rate fluctuations. The forward looking statements contained in this document speak only as of the date of this document and each of the Company, respective directors, officers, employees, agents, representatives and/or advisers expressly disclaims any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this document.